DE69919713T2 - Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium - Google Patents

Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium Download PDF

Info

Publication number
DE69919713T2
DE69919713T2 DE69919713T DE69919713T DE69919713T2 DE 69919713 T2 DE69919713 T2 DE 69919713T2 DE 69919713 T DE69919713 T DE 69919713T DE 69919713 T DE69919713 T DE 69919713T DE 69919713 T2 DE69919713 T2 DE 69919713T2
Authority
DE
Germany
Prior art keywords
coating
phenytoin sodium
phenytoin
enteric
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69919713T
Other languages
German (de)
English (en)
Other versions
DE69919713D1 (de
Inventor
Elliott Beiman
Fred Landsman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cascade Development Inc
Original Assignee
Cascade Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/111,188 external-priority patent/US5968554A/en
Application filed by Cascade Development Inc filed Critical Cascade Development Inc
Application granted granted Critical
Publication of DE69919713D1 publication Critical patent/DE69919713D1/de
Publication of DE69919713T2 publication Critical patent/DE69919713T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69919713T 1998-07-07 1999-06-25 Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium Expired - Lifetime DE69919713T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/111,188 US5968554A (en) 1998-07-07 1998-07-07 Sustained release pharmaceutical preparation
US111188 1998-07-07
US338716 1999-06-23
US09/338,716 US6312728B1 (en) 1998-07-07 1999-06-23 Sustained release pharmaceutical preparation
PCT/US1999/014204 WO2000001369A1 (en) 1998-07-07 1999-06-25 Sustained release pharmaceutical preparation

Publications (2)

Publication Number Publication Date
DE69919713D1 DE69919713D1 (de) 2004-09-30
DE69919713T2 true DE69919713T2 (de) 2005-09-22

Family

ID=26808709

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69919713T Expired - Lifetime DE69919713T2 (de) 1998-07-07 1999-06-25 Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium

Country Status (10)

Country Link
US (1) US6312728B1 (enExample)
EP (1) EP1094790B9 (enExample)
JP (1) JP2003524592A (enExample)
AT (1) ATE274344T1 (enExample)
AU (1) AU5084299A (enExample)
CA (1) CA2337046C (enExample)
DE (1) DE69919713T2 (enExample)
ES (1) ES2226412T3 (enExample)
IL (1) IL140761A0 (enExample)
WO (1) WO2000001369A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US6572889B1 (en) 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US20040043067A1 (en) * 2002-06-19 2004-03-04 Salamone Joseph C. Fluorosiloxane matrix controlled diffusion drug delivery systems
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
BR0315731A (pt) * 2002-10-30 2005-09-06 Pharmacia Corp Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
JP2007507491A (ja) * 2003-09-29 2007-03-29 シージェー コーポレーション 徐放性製剤
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
WO2005117697A2 (en) * 2004-05-28 2005-12-15 Narayanan Ramasubramanian Unified indigestion package and process for patient compliance with prescribed medication regimen
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
ME01316B (me) 2004-08-13 2013-12-20 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
UA88477C2 (ru) 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
BRPI0707736A2 (pt) 2006-02-13 2011-05-10 Vanda Pharmaceuticals Inc formulaÇÕes de imidazolilalquil-piridinas de dosagem estÁvel
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
EP2222301B1 (en) * 2007-12-13 2014-10-08 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
EP2222300B1 (en) 2007-12-13 2014-06-11 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
BR112022012514A2 (pt) 2019-12-27 2022-09-06 Evelo Biosciences Inc Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
WO2021146523A1 (en) 2020-01-17 2021-07-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
CN115551486A (zh) 2020-04-17 2022-12-30 伊夫罗生物科学公司 具有改善的崩解谱的固体剂型
AU2021342481A1 (en) 2020-09-18 2023-05-04 Evelo Biosciences, Inc. Solid dosage forms of bacteria
US20240024377A1 (en) 2020-10-29 2024-01-25 Evelo Biosciences, Inc. Compositions comprising spirulina components
JP2024501481A (ja) 2020-12-14 2024-01-12 エヴェロ バイオサイエンシズ，インコーポレーテッド 細胞外小胞調製物
WO2022140396A1 (en) 2020-12-22 2022-06-30 Evelo Biosciences, Inc. Compositions comprising animal hemoglobin
US20240423924A1 (en) 2021-01-26 2024-12-26 Evelo Biosciences, Inc. Prevotella extracellular vesicle preparations
EP4297762A1 (en) 2021-02-26 2024-01-03 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187578A1 (en) 2021-03-05 2022-09-09 Evelo Biosciences, Inc. Solid dosage forms
TW202304415A (zh) 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
WO2022221183A1 (en) 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
WO2023049268A1 (en) 2021-09-24 2023-03-30 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023114293A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023183396A1 (en) 2022-03-22 2023-09-28 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023200837A1 (en) 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
WO2024102226A1 (en) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994260A (en) 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
IL95423A (en) * 1989-09-21 1994-11-11 American Cyanamid Co Pulsatile once-a-day delivery systems for minocycline
EP0497977B1 (en) * 1989-10-26 1995-03-15 Nippon Shinyaku Company, Limited Gastric preparation
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5188836A (en) 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US5968554A (en) * 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
EP1094790B9 (en) 2005-05-04
WO2000001369A1 (en) 2000-01-13
EP1094790B1 (en) 2004-08-25
CA2337046C (en) 2005-08-16
EP1094790A1 (en) 2001-05-02
AU5084299A (en) 2000-01-24
ES2226412T3 (es) 2005-03-16
IL140761A0 (en) 2002-02-10
US6312728B1 (en) 2001-11-06
CA2337046A1 (en) 2000-01-13
EP1094790A4 (en) 2003-03-12
JP2003524592A (ja) 2003-08-19
ATE274344T1 (de) 2004-09-15
DE69919713D1 (de) 2004-09-30

Similar Documents

Publication Publication Date Title
DE69205971T2 (de) Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten.
EP1094790B9 (en) Sustained release pharmaceutical preparation comprising phenytoin sodium
DE69003568T2 (de) Arzneimittel mit verzögerter Freigabe.
DE3688532T2 (de) Pharmazeutische darreichungsform mit verzoegerter abgabe.
EP0519870B1 (de) Neue orale Diclofenaczubereitung
DE69727153T2 (de) Im magen verweilende orale arzneistoffdosisformen zur gesteuerten freisetzung schwerlöslicher arzneistoffe und unlöslicher stoffe
DE69917937T2 (de) Formulierungen mit gesteuerter freisetzung, die einen schnellen eintritt und einen schnellen abfall der wirksamen arzneistoffplasmakonzentrationen haben
DE69432618T2 (de) Arzneimittel mit gesteuertem Beginn und gesteuerter Rate der Freisetzung
DE69832731T2 (de) Arzneimittel mit magensaftresistentem überzug und methode zur herstellung
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE60036874T2 (de) Pellet formulierung mit gesteuerter freisetzung
DE3586600T2 (de) Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
DE69632753T2 (de) Darifenacin enthaltende pharmazeutische Zubereitungen
EP0977557B1 (de) Pellet-formulierung zur behandlung des intestinaltraktes
DE69022876T2 (de) Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.
DE69529050T2 (de) Orale dosierungsformen mit pulverschicht
US5968554A (en) Sustained release pharmaceutical preparation
DE69122751T2 (de) Arzneimittelzusammensetzung mit kontrollierter wirkstoffabgabe
DE20219293U1 (de) Pharmazeutische Pellets enthaltend Tamsulosin
EP1113787A1 (de) Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung
DD298350A5 (de) Verfahren zur herstellung von pharmazeutischen praeparaten mit verzoegerter wirkstoffabgabe
EP0615442B1 (de) Sol-gesteuerte thermokolloidmatrix auf gelatine basis für perorale retardformen
CH705273B1 (de) Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon.
DE69817848T2 (de) Monolithsysteme enthaltend mindestens einer wirkstoff, bestehend aus drei schichten mit unterschiedlichen freisetzungmechanismus
DE3856555T2 (de) Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption

Legal Events

Date Code Title Description
8364 No opposition during term of opposition